Accuray Launches Synchrony® Motion Tracking and Correction Technology for the Radixact® System

SUNNYVALE, Calif., April 24, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the launch of its Synchrony^® motion tracking and correction technology¹ to be used with the Radixact^® System. This new feature adds intrafraction motion synchronization capabilities to the Radixact System, enabling real-time tracking, visualization and correction for tumor motion during treatment, with the goal of improving dose accuracy and treatment times compared to conventional radiation therapy systems. Clinicians attending the European Society for Radiotherapy & Oncology (ESTRO) meeting are invited to help celebrate the unveiling of the Radixact System with Synchrony on Friday, April 26, 2019 at 8:00 pm at Accuray booth #800.

Originally developed to expand on the CyberKnife^® System's unique automatic motion tracking and correction capabilities, Synchrony is the only technology that uses continual image guidance to automatically adjust the movement of the beam in synchronization with the movement of the target volume. Synchrony for the Radixact System is designed to correct for tumors that move as a result of bodily processes, including respiration and digestion, as well as patient movement, and has the capability to perform fiducial-free tracking for lung indications.

The Radixact System is equipped with a built-in CT scanner that performs daily imaging before each treatment session, providing clinicians with information on the shape and position of the tumor and making it possible for them to identify and correct for any variations in patient positioning. Clinicians are then able to use Synchrony to automatically synchronize radiation treatment delivery to the moving tumor's location throughout the treatment session. This functionality is designed to provide highly precise radiation dose delivery to tumors that move, such as lung and prostate, and smaller treatment margins around the tumor, minimizing the amount of healthy tissue exposed to high-dose radiation.

"Adding the Synchrony motion tracking and correction feature to our Radixact System is the natural next step on the system's product development roadmap. Accuray is committed to delivering product improvements that enable clinicians to optimize their experience and use of our technology long-term," said Birgit Fleurent, Chief Marketing Officer at Accuray. "We expect to begin shipping the Synchrony technology commercially by the end of calendar year 2019."

Jennifer Smilowitz, PhD, clinical professor University of Wisconsin School of Medicine and Public Health, and Fellow of the American Association of Physicists in Medicine (AAPM), has been involved in the development of the Radixact System from its start. She comments, "The introduction of Synchrony for this system will enable clinicians to more easily, and efficiently, deliver precise radiation treatments to tumors that move using image-guided, intensity-modulated radiation therapy (IG-IMRT) with target tracking. In my opinion, this has the potential to expand the way the Radixact System is used, as well as the types of patients who are treated with it."

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, the expected timing for shipping the Synchrony technology commercially, and the ability of new product improvements to expand on the use of the Radixact^® System as well as the type of patients treated with it. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product offerings and improvements; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products, including product improvements, for certain users and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 8, 2019 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contacts
Beth Kaplan                                                                 
Public Relations Director, Accuray                                
+1 (408) 789-4426                                                         
[email protected] 

Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
[email protected]

¹ "Synchrony^® Motion Tracking and Correction Technology" is synonymous with the development name: "Motion Tracking and Compensation Feature for the Radixact^® Treatment Delivery System"

View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-launches-synchrony-motion-tracking-and-correction-technology-for-the-radixact-system-300836858.html

SOURCE Accuray Incorporated